Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.21 -0.04 (-0.07%)

Delayed Quote Updated: 11:23 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

38 39 Next >

Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs

November 03, 2022

From Genentech

Via Business Wire

6 ETFs That Are All You Need for Retirement ↗

October 30, 2022

These yield-producing stock and bond funds are all down less than the S&P 500 this year.

Via The Motley Fool

15 Global Psychedelics Executives To Keep An Eye On In 2022 ↗

October 28, 2022

As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list...

Via Benzinga

Biogen To Report Q3 Earnings: Here's What To Expect ↗

October 21, 2022

Biogen will report third-quarter 2022 results on Oct 25, before market open.

Via Talk Markets

Most Active On The OTC Markets In September – A Look Back As October Comes To A Close

October 28, 2022

By Jad Malaeb, Benzinga

Via News Direct

Topics ETFs Stocks

Most Active On The OTC Markets In September – A Look Back As October Comes To A Close

October 28, 2022

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ) and the SPDR Dow Jones Industrial Average...

Via TheNewswire.com

Topics ETFs Stocks

Most Active On The OTC Markets In September – A Look Back As October Comes To A Close ↗

October 27, 2022

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022.

Via Benzinga

Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)

October 27, 2022

From Genentech

Via Business Wire

Early Treatment With Genentech’s Ocrevus (ocrelizumab) Leads to Reduced Disease Progression and Healthcare Costs; Nine-Year Safety Data Reinforce Favorable Benefit-Risk Profile

October 26, 2022

From Genentech

Via Business Wire

Analyst Bullish On SQZ Biotech's Technology For Solving Cell Therapy Challenges ↗

October 20, 2022

Via Benzinga

Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022

October 19, 2022

From Genentech

Via Business Wire

Roche Posts Lower Quarterly Sales As Demand For COVID Products Slide ↗

October 18, 2022

Via Benzinga

Market Sentiment Improves Amid Earnings Season ↗

October 18, 2022

The fourth quarter started on a sour note as geopolitical tensions and recession fears triggered a risk-averse mood, but earnings season has started since then, focusing market participants’ attention...

Via Talk Markets

Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million ↗

October 15, 2022

Deals, financings, trials and approvals on the China biotech/pharma market.

Via Talk Markets

Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts ↗

October 13, 2022

Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's.

Via Benzinga

Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity ↗

October 13, 2022

Even a percentage of the Alzheimer's market could mean $7 billion for Biogen.

Via Investor's Business Daily

Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients ↗

October 12, 2022

Via Benzinga

Roche To Introduce Next-Generation Portfolio Of COVID-19 Rapid Tests ↗

October 12, 2022

Via Benzinga

Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)

October 12, 2022

From Genentech

Via Business Wire

Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers ↗

October 10, 2022

Via Benzinga

EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility ↗

October 03, 2022

Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California.

Via Benzinga

Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review ↗

September 30, 2022

The major indexes fell, with the S&P 500 breaking below bear market lows.

Via Investor's Business Daily

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win ↗

September 28, 2022

Via Benzinga

This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval ↗

September 28, 2022

Via Benzinga

2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data ↗

September 28, 2022

Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd.

Via Benzinga

FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests ↗

September 27, 2022

Via Benzinga

COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns ↗

September 23, 2022

The World Health Organization (WHO) warned that it struggles to identify and

Via Benzinga

Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger ↗

September 19, 2022

Via Benzinga

Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders ↗

September 19, 2022

Via Benzinga

WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete ↗

September 16, 2022

Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies.

Via Benzinga

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.